Skip to main content

Advertisement

Table 4 Baseline characteristics according to pocket hematoma

From: Bleeding complications during cardiac electronic device implantation in patients receiving antithrombotic therapy: is there any value of local tranexamic acid?

Variables PH positive group (n = 26) PH negative group (n = 109) P-value
Age 64 ± 12 59 ± 11 0.037
Male, n (%) 14 (53.8) 67 (61.5) 0.624
Body mass index (kg/m2) 26.1 ± 5.7 25.3 ± 4.3 0.396
Smoking, n (%) 3 (11.5) 19 (17.4) 0.567
Hypertension, n (%) 18 (69.2) 56 (51.4) 0.154
Diabetes mellitus, n (%) 7 (26.9) 39 (35.8) 0.531
Previous CABG, n (%) 9 (34.6) 34 (31.2) 0.918
Ejection fraction, % 32 (25–55) 34 (20–55) 0.210
COPD, n (%) 3 (11.5) 16 (14.7) 1.0
Hemoglobin, g/dL 13.2 (10.8–15.1) 12.8 (9.5–14.5) 0.946
Platelet count, K/mm3 239 ± 69 246 ± 55 0.630
BUN, mg/dL 30.2 (25–39) 31.6 (22–45) 0.975
Creatinine, mg/dL 1.0 ± 0.4 1.1 ± 0.4 0.614
Atrial fibrillation, n (%) 10 (38.5) 33 (30.3) 0.568
Metallic prosthetic valve, n (%) 11 (42.3) 43 (39.4) 0.964
LV thrombus, n (%) 4 (15.4) 5 (4.6) 0.069
Recent stent implantation, n (%) 23 (88.5) 40 (36.7) <0.001
Medications
ACEI/ARB, n (%) 22 (84.6) 73 (67.0) 0.126
Beta blocker, n (%) 24 (92.3) 88 (80.7) 0.245
Diuretic, n (%) 21 (80.8) 78 (71.6) 0.479
Spironolactone, n (%) 19 (73.1) 48 (44.0) 0.015
Statin, n (%) 13 (50.0) 49 (45.0) 0.807
Warfarin, n (%) 4 (15.4) 68 (62.4) <0.001
DAPT, n (%) 7 (26.9) 30 (27.5) 1.0
Warfarin plus DAPT, n (%) 15 (57.7) 11 (10.1) <0.001
  1. ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BUN blood urea nitrogen, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, DAPT dual antiplatelet therapy, LV left ventricular, PH pocket hematoma